PDC*line Pharma
- Biotech or pharma, therapeutic R&D
PDC*line Pharma (www.pdc-line-pharma.com) is a clinical-stage biotech company developing a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Born from the innovative research at the French Blood Bank (EFS), we reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase II trial in lung cancer and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M and signed a €108M licensing deal in Asia with a Korean pharmaceutical company, LG Chem Life Science. PDC*line Pharma comprises 41 team members across Belgium (Liège, headquarters), France (Grenoble) and South Korea (Seoul).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}